Literature DB >> 9713302

Ki-ras mutations and prognosis in colorectal cancer.

U Kressner1, J Bjørheim, S Westring, S S Wahlberg, L Påhlman, B Glimelius, G Lindmark, A Lindblom, A L Børresen-Dale.   

Abstract

A total of 191 colorectal adenocarcinomas, obtained from consecutive patients with a median follow-up of 6 years, were studied in order to evaluate the possible association of Ki-ras mutations with tumour stage, tumour differentiation and survival time. Resected full-cross tumour samples were screened for Ki-ras mutations in codons 12 and 13 using temporal temperature gradient gel electrophoresis (TTGE). Ki-ras mutations were detected in 62 (32%) of the samples. The most frequent mutation, observed in 21 samples, was from GGT to GAT changing glycine to aspartic acid in codon 12. The study did not show any association between Ki-ras mutations and Dukes' stage or tumour differentiation. Patients with Ki-ras mutations had a marginally shorter survival time (median 50 months) compared with patients without (median 59 months), but the difference was not statistically significant. The results indicate that Ki-ras gene mutations have no relevant prognostic importance in this cohort of colorectal cancer patients.

Entities:  

Mesh:

Year:  1998        PMID: 9713302     DOI: 10.1016/s0959-8049(97)10111-3

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  17 in total

Review 1.  The angiogenic switch molecule, secreted FGF-binding protein, an indicator of early stages of pancreatic and colorectal adenocarcinoma.

Authors:  Elena Tassi; Anton Wellstein
Journal:  Semin Oncol       Date:  2006-12       Impact factor: 4.929

Review 2.  KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program.

Authors:  J H J M van Krieken; A Jung; T Kirchner; F Carneiro; R Seruca; F T Bosman; P Quirke; J F Fléjou; T Plato Hansen; G de Hertogh; P Jares; C Langner; G Hoefler; M Ligtenberg; D Tiniakos; S Tejpar; G Bevilacqua; A Ensari
Journal:  Virchows Arch       Date:  2008-09-18       Impact factor: 4.064

3.  Associations of Ki-ras proto-oncogene mutation and p53 gene overexpression in sporadic colorectal adenomas with demographic and clinicopathologic characteristics.

Authors:  Janine G Einspahr; Maria Elena Martinez; Ruiyun Jiang; Chiu-Hsieh Hsu; Asif Rashid; Achyut K Bhattacharrya; Dennis J Ahnen; Elizabeth T Jacobs; P Scott Houlihan; C Renee Webb; David S Alberts; Stanley R Hamilton
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-08       Impact factor: 4.254

Review 4.  A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy.

Authors:  Vanessa Deschoolmeester; Marc Baay; Pol Specenier; Filip Lardon; Jan B Vermorken
Journal:  Oncologist       Date:  2010-06-28

5.  K-ras mutation in the major duodenal papilla and gastric and colonic mucosa in patients with autoimmune pancreatitis.

Authors:  Terumi Kamisawa; Shin-Ichirou Horiguchi; Yukiko Hayashi; Xiaoqing Yun; Toshikazu Yamaguchi; Koji Tsuruta; Tsuneo Sasaki
Journal:  J Gastroenterol       Date:  2010-02-16       Impact factor: 7.527

6.  Clinical significance of K-ras and BRAF mutations in Chinese colorectal cancer patients.

Authors:  Hong Shen; Ying Yuan; Han-Guang Hu; Xian Zhong; Xiao-Xian Ye; Mo-Dan Li; Wei-Jia Fang; Shu Zheng
Journal:  World J Gastroenterol       Date:  2011-02-14       Impact factor: 5.742

Review 7.  Is there a genetic signature for liver metastasis in colorectal cancer?

Authors:  Cristina Nadal; Joan Maurel; Pere Gascon
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

8.  Tumor angiogenesis: initiation and targeting - therapeutic targeting of an FGF-binding protein, an angiogenic switch molecule, and indicator of early stages of gastrointestinal adenocarcinomas -.

Authors:  Elena Tassi; Anton Wellstein
Journal:  Cancer Res Treat       Date:  2006-12-31       Impact factor: 4.679

Review 9.  Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma.

Authors:  Geoffrey T Gibney; Jane L Messina; Inna V Fedorenko; Vernon K Sondak; Keiran S M Smalley
Journal:  Nat Rev Clin Oncol       Date:  2013-05-28       Impact factor: 66.675

Review 10.  Molecular lesions in colorectal cancer: impact on prognosis? Original data and review of the literature.

Authors:  B Klump; O Nehls; T Okech; C-J Hsieh; V Gaco; F S Gittinger; M Sarbia; F Borchard; A Greschniok; H H Gruenagel; R Porschen; M Gregor
Journal:  Int J Colorectal Dis       Date:  2003-06-21       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.